- |||||||||| alirinetide (GM604) / Genervon
[VIRTUAL] GM6 attenuates Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. () - Aug 2, 2021 - Abstract #AAIC2021AAIC_2431; In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation.
- |||||||||| GM602 / Genervon
Trial completion, Trial primary completion date: GMAIS: Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (clinicaltrials.gov) - Aug 2, 2017 P2, N=34, Completed, In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jul 2016
- |||||||||| GM608 / Genervon
Trial completion, Trial primary completion date: Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - Aug 20, 2015 P2a, N=6, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
|